Allergan (AGN) is expected to report Q4 earnings before the market open on Thursday, February 2, with a conference call scheduled for 11:00 am ET.
The consensus estimate is $1.00 for EPS and $1.4B for revenue, according to First Call. The consensus range is 97c-$1.02 for EPS, and $1.36B-$1.43B for revenue, according to First Call. On October 26, Allergan reported Q3 EPS 92c, beating consensus estimates of 90c, with revenue for Q3 missing consensus estimates of $1.33B slightly. The company guided for Q4 EPS to come in at 97-99c on revenue of $1.33-$1.4B. A positive catalyst for Q4 may be seen coming from an incremental improvement in the U.S. economy and stock market performance since the October quarter, which may have spurred more discretionary spending on vanity procedures. Investors will be listening for the progress of the Botox chronic migraine launch in the U.S. One possible headwind for the company may be slowing North American implant sales that the company referred to on its Q3 earnings conference call.
On January 4, Leerink raised its target on the shares to $96-$97 from $92-$93 citing FY12 Botox growth expectations. The firm maintains an Outperform on the stock.